Cargando…

Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study

BACKGROUND: The long-term risks and time trends of subsequent primary neoplasms (SPNs) among Ewing (ES) and osteosarcoma (OS) survivors are not fully understood. METHODS: We performed a nationwide study of all ES and OS patients identified in the Swedish Cancer Registry from 1958 to 2015 with up to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hesla, Asle Charles, Discacciati, Andrea, Tsagkozis, Panagiotis, Smedby, Karin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156510/
https://www.ncbi.nlm.nih.gov/pubmed/32066914
http://dx.doi.org/10.1038/s41416-020-0748-3
_version_ 1783522223414312960
author Hesla, Asle Charles
Discacciati, Andrea
Tsagkozis, Panagiotis
Smedby, Karin E.
author_facet Hesla, Asle Charles
Discacciati, Andrea
Tsagkozis, Panagiotis
Smedby, Karin E.
author_sort Hesla, Asle Charles
collection PubMed
description BACKGROUND: The long-term risks and time trends of subsequent primary neoplasms (SPNs) among Ewing (ES) and osteosarcoma (OS) survivors are not fully understood. METHODS: We performed a nationwide study of all ES and OS patients identified in the Swedish Cancer Registry from 1958 to 2015 with up to 58 years of follow-up. The risk of SPN was compared with that of the general population using standardised incidence ratios (SIRs) and absolute excess risks (AERs). RESULTS: One hundred and fifteen SPNs were diagnosed among 1779 patients with ES or OS, yielding an overall SIR of 2.3 (95% confidence interval (CI), 1.9–2.7). The risk remained significantly increased in the latest treatment era (SIR(2000-2015) 2.0; 95% CI, 1.1–3.5). The highest absolute excess risks (AER) was due to breast cancer (AER 15.2/10,000 person-years; 95% CI, 5.0–29.8) followed by female genital malignancies (AER 9.5/10,000 person-years; 95% CI, 2.4–21.5). The excess breast cancer risk among ES survivors was noted also after 30 years of follow-up with 127 extra breast cancers/10,000 person-years (95% CI, 6.6–419). CONCLUSIONS: Breast- and female genital malignancies contribute most to the excess risk of SPN among ES and OS survivors. Importantly, excess risks did not decline over calendar time or long-term follow-up.
format Online
Article
Text
id pubmed-7156510
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71565102021-02-18 Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study Hesla, Asle Charles Discacciati, Andrea Tsagkozis, Panagiotis Smedby, Karin E. Br J Cancer Article BACKGROUND: The long-term risks and time trends of subsequent primary neoplasms (SPNs) among Ewing (ES) and osteosarcoma (OS) survivors are not fully understood. METHODS: We performed a nationwide study of all ES and OS patients identified in the Swedish Cancer Registry from 1958 to 2015 with up to 58 years of follow-up. The risk of SPN was compared with that of the general population using standardised incidence ratios (SIRs) and absolute excess risks (AERs). RESULTS: One hundred and fifteen SPNs were diagnosed among 1779 patients with ES or OS, yielding an overall SIR of 2.3 (95% confidence interval (CI), 1.9–2.7). The risk remained significantly increased in the latest treatment era (SIR(2000-2015) 2.0; 95% CI, 1.1–3.5). The highest absolute excess risks (AER) was due to breast cancer (AER 15.2/10,000 person-years; 95% CI, 5.0–29.8) followed by female genital malignancies (AER 9.5/10,000 person-years; 95% CI, 2.4–21.5). The excess breast cancer risk among ES survivors was noted also after 30 years of follow-up with 127 extra breast cancers/10,000 person-years (95% CI, 6.6–419). CONCLUSIONS: Breast- and female genital malignancies contribute most to the excess risk of SPN among ES and OS survivors. Importantly, excess risks did not decline over calendar time or long-term follow-up. Nature Publishing Group UK 2020-02-18 2020-04-14 /pmc/articles/PMC7156510/ /pubmed/32066914 http://dx.doi.org/10.1038/s41416-020-0748-3 Text en © The Author(s), under exclusive licence to Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Article
Hesla, Asle Charles
Discacciati, Andrea
Tsagkozis, Panagiotis
Smedby, Karin E.
Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study
title Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study
title_full Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study
title_fullStr Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study
title_full_unstemmed Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study
title_short Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study
title_sort subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156510/
https://www.ncbi.nlm.nih.gov/pubmed/32066914
http://dx.doi.org/10.1038/s41416-020-0748-3
work_keys_str_mv AT heslaaslecharles subsequentprimaryneoplasmsamongbonesarcomasurvivorsincreasedrisksremainafter30yearsoffollowupandinthelatesttreatmenteraanationwidepopulationbasedstudy
AT discacciatiandrea subsequentprimaryneoplasmsamongbonesarcomasurvivorsincreasedrisksremainafter30yearsoffollowupandinthelatesttreatmenteraanationwidepopulationbasedstudy
AT tsagkozispanagiotis subsequentprimaryneoplasmsamongbonesarcomasurvivorsincreasedrisksremainafter30yearsoffollowupandinthelatesttreatmenteraanationwidepopulationbasedstudy
AT smedbykarine subsequentprimaryneoplasmsamongbonesarcomasurvivorsincreasedrisksremainafter30yearsoffollowupandinthelatesttreatmenteraanationwidepopulationbasedstudy